Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Total 13F shares
-
106,173,637
-
Share change
-
+5,674,785
-
Total reported value
-
$402,396,029
-
Put/Call ratio
-
177%
-
Price per share
-
$3.79
-
Number of holders
-
131
-
Value change
-
+$22,237,368
-
Number of buys
-
65
-
Number of sells
-
55
Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q2 2021
As of 30 Jun 2021,
Akebia Therapeutics, Inc. - Common Stock (AKBA) was held by
131 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
106,173,637 shares.
The largest 10 holders included
STATE STREET CORP, BlackRock Inc., VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, Nantahala Capital Management, LLC, JPMORGAN CHASE & CO, SATTER MANAGEMENT CO., L.P., MARSHALL WACE, LLP, DIMENSIONAL FUND ADVISORS LP, and GOLDMAN SACHS GROUP INC.
This page lists
131
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.